Literature DB >> 12802875

SEE locomotor behavior test discriminates C57BL/6J and DBA/2J mouse inbred strains across laboratories and protocol conditions.

Neri Kafkafi1, Dina Lipkind, Yoav Benjamini, Cheryl L Mayo, Gregory I Elmer, Ilan Golani.   

Abstract

Conventional tests of behavioral phenotyping frequently have difficulties differentiating certain genotypes and replicating these differences across laboratories and protocol conditions. This study explores the hypothesis that automated tests can be designed to quantify ethologically relevant behavior patterns that more readily characterize heritable and replicable phenotypes. It used SEE (Strategy for the Exploration of Exploration) to phenotype the locomotor behavior of the C57BL/6 and DBA/2 mouse inbred strains across 3 laboratories. The 2 genotypes differed in 15 different measures of behavior, none of which had a significant genotype-laboratory interaction. Within the same laboratory, most of these differences were replicated in additional experiments despite the test photoperiod phase being changed and saline being injected. Results suggest that well-designed tests may considerably enhance replicability across laboratories.

Entities:  

Mesh:

Year:  2003        PMID: 12802875     DOI: 10.1037/0735-7044.117.3.464

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  24 in total

1.  Genotype-environment interactions in mouse behavior: a way out of the problem.

Authors:  Neri Kafkafi; Yoav Benjamini; Anat Sakov; Greg I Elmer; Ilan Golani
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-11       Impact factor: 11.205

2.  Intrasession and intersession habituation in mice: from inbred strain variability to linkage analysis.

Authors:  Valerie J Bolivar
Journal:  Neurobiol Learn Mem       Date:  2009-09       Impact factor: 2.877

3.  The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Authors:  A Reiner; D C Lafferty; H B Wang; N Del Mar; Y P Deng
Journal:  Neurobiol Dis       Date:  2012-03-27       Impact factor: 5.996

4.  Drug discovery in psychiatric illness: mining for gold.

Authors:  Greg I Elmer; Neri Kafkafi
Journal:  Schizophr Bull       Date:  2009-03-18       Impact factor: 9.306

5.  Performance of C57BL/6J and DBA/2J mice on a touchscreen-based attentional set-shifting task.

Authors:  Price E Dickson; Michele A Calton; Guy Mittleman
Journal:  Behav Brain Res       Date:  2013-12-18       Impact factor: 3.332

6.  A novel method for automatic quantification of psychostimulant-evoked route-tracing stereotypy: application to Mus musculus.

Authors:  Stephen J Bonasera; A Katrin Schenk; Evan J Luxenberg; Laurence H Tecott
Journal:  Psychopharmacology (Berl)       Date:  2007-12-21       Impact factor: 4.530

7.  A Novel Closed-Head Model of Mild Traumatic Brain Injury Using Focal Primary Overpressure Blast to the Cranium in Mice.

Authors:  Natalie H Guley; Joshua T Rogers; Nobel A Del Mar; Yunping Deng; Rafiqul M Islam; Lauren D'Surney; Jessica Ferrell; Bowei Deng; Jessica Hines-Beard; Wei Bu; Huiling Ren; Andrea J Elberger; Jeffrey G Marchetta; Tonia S Rex; Marcia G Honig; Anton Reiner
Journal:  J Neurotrauma       Date:  2015-12-17       Impact factor: 5.269

8.  Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress.

Authors:  Mohammed Ragab Abdel-Aziz Ali; Amira Morad Hussein Abo-Youssef; Basim Anwar Shehata Messiha; Mahmoud Mohamed Khattab
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-03-30       Impact factor: 3.000

Review 9.  A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor.

Authors:  Jared W Young; Arpi Minassian; Martin P Paulus; Mark A Geyer; William Perry
Journal:  Neurosci Biobehav Rev       Date:  2007-06-05       Impact factor: 8.989

10.  Perindopril ameliorates experimental Alzheimer's disease progression: role of amyloid β degradation, central estrogen receptor and hyperlipidemic-lipid raft signaling.

Authors:  Basim A S Messiha; Mohammed R A Ali; Mahmoud M Khattab; Amira M Abo-Youssef
Journal:  Inflammopharmacology       Date:  2020-06-01       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.